Banner Alzheimer's Institute

Migration, Crosslink

📖

Banner Alzheimer's Institute

active

wiki page Created: 2026-04-02T07:20:10 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-institutions-banner-alzheimers-inst

📖 Wiki Page

institution2210 wordssynced 2026-04-02

Introduction

Banner Alzheimer'S Institute is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

flowchart TD institutions_banner_alzheimers["Banner Alzheimers Institute"] style institutions_banner_alzheimers fill:#4fc3f7,stroke:#333,color:#000 institutions_banner__0["Basic Information"] institutions_banner_alzheimers -->|"includes"| institutions_banner__0 style institutions_banner__0 fill:#81c784,stroke:#333,color:#000 institutions_banner__1["History"] institutions_banner_alzheimers -->|"includes"| institutions_banner__1 style institutions_banner__1 fill:#ef5350,stroke:#333,color:#000 institutions_banner__2["Research Focus"] institutions_banner_alzheimers -->|"includes"| institutions_banner__2 style institutions_banner__2 fill:#ffd54f,stroke:#333,color:#000 institutions_banner__3["Alzheimers Disease Research"] institutions_banner_alzheimers -->|"includes"| institutions_banner__3 style institutions_banner__3 fill:#ce93d8,stroke:#333,color:#000 institutions_banner__4["Parkinsons Disease Research"] institutions_banner_alzheimers -->|"includes"| institutions_banner__4 style institutions_banner__4 fill:#4fc3f7,stroke:#333,color:#000 institutions_banner__5["Neurodegeneration Mechanisms"] institutions_banner_alzheimers -->|"includes"| institutions_banner__5 style institutions_banner__5 fill:#81c784,stroke:#333,color:#000

...

Introduction

Banner Alzheimer'S Institute is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Mermaid diagram (expand to render)

The Banner Alzheimer's Institute (BAI) is a leading center for Alzheimer's disease research, clinical care, and prevention. Part of Banner Health, one of the largest nonprofit health care systems in the United States, BAI focuses on groundbreaking Alzheimer's prevention trials and comprehensive patient care. Located in Phoenix, Arizona, the institute has established itself as a global leader in Alzheimer's disease research, particularly in the areas of prevention, early detection, and novel therapeutic approaches [1]. [@reiman2012]

The institute was founded in 2006 with a mission to accelerate the development of effective Alzheimer's disease treatments and ultimately find a cure. Under the leadership of renowned Alzheimer's researcher Dr. Eric Reiman, BAI has become known for its innovative approach to clinical trials, including the pioneering use of preclinical biomarkers to identify individuals at risk for Alzheimer's before symptoms appear [2]. [@li2007]

Basic Information

<div class="infobox infobox-institution"> [@langbaum2013]
<table> [@fleisher2012]
<tr><th colspan="2" style="background:#f0f0f0;">Banner Alzheimer's Institute</th></tr> [@alzheimers2014]
<tr><td><b>Location</b></td><td>Phoenix, Arizona, USA</td></tr> [@cummings2014]
<tr><td><b>Type</b></td><td>Medical Research Institute</td></tr> [@singleton2013]
<tr><td><b>Founded</b></td><td>2006</td></tr> [@reiman2016]
<tr><td><b>Website</b></td><td><a href="https://www.bannerhealth.com/services/alzheimers" target="_blank">Official Website</a></td></tr> [@alzheimer2019]
<tr><td><b>Affiliation</b></td><td>Banner Health</td></tr> [@blennow2015]
</table> [@morris2016]
</div> [@national2020]

History

Banner Alzheimer's Institute was established in 2006 as part of Banner Health's commitment to addressing the growing Alzheimer's disease crisis. The institute built upon the foundation of the Arizona Alzheimer's Consortium, a statewide collaborative research effort [3].

In its early years, BAI focused on developing and validating biomarkers for Alzheimer's disease detection and establishing the Alzheimer's Prevention Registry, a nationwide program to recruit individuals at risk for Alzheimer's into clinical trials [4]. The institute has since expanded its scope to include comprehensive clinical care programs, basic science research, and training the next generation of Alzheimer's researchers.

Research Focus

Alzheimer's Disease Research

The institution conducts comprehensive Alzheimer's disease research spanning basic science, clinical trials, and patient care. Key areas include:

Preclinical Detection: Using PET imaging, CSF biomarkers, and genetic testing to identify individuals at risk before symptoms appear [5]
Prevention Trials: Leading international efforts to test treatments that may prevent or delay Alzheimer's in at-risk individuals, including the Alzheimer's Prevention Initiative (API) [6]
Treatment Development: Testing novel therapeutic agents targeting [amyloid-beta](/proteins/amyloid-beta), [tau](/proteins/tau), and other disease mechanisms [7]

Parkinson's Disease Research

Researchers investigate [Parkinson's disease](/diseases/parkinsons-disease) mechanisms, biomarkers, and therapeutic targets. BAI scientists study [alpha-synuclein](/proteins/alpha-synuclein) aggregation, dopamine neuron function, and genetic risk factors including [LRRK2](/entities/lrrk2) and [GBA](/entities/gba) mutations [8].

Neurodegeneration Mechanisms

Studies include protein aggregation, mitochondrial dysfunction, neuroinflammation, and synaptic loss in neurodegenerative diseases. The institute maintains robust basic science programs investigating the fundamental biology of neurodegeneration.

Notable Programs

Alzheimer's Prevention Initiative (API): An international collaborative effort to evaluate treatments in individuals at highest genetic risk for Alzheimer's disease [9]
Alzheimer's Prevention Registry: A nationwide registry that has enrolled over 300,000 individuals interested in participating in prevention research [10]
Biomarker Development Program: Research into early detection and progression biomarkers using PET imaging, CSF analysis, and blood tests [11]
Comprehensive Care Center: Providing state-of-the-art clinical care for patients with Alzheimer's and related dementias [12]

Key Research Areas

| Disease | Focus Areas | Current Status |
|---------|-------------|----------------|
| Alzheimer's Disease | Amyloid, [tau](/proteins/tau), neuroinflammation, clinical trials | Active prevention trials |
| Parkinson's Disease | [Alpha-synuclein](/proteins/alpha-synuclein), dopamine, LRRK2, GBA | Observational studies |
| ALS | SOD1, [TDP-43](/proteins/tdp-43), [C9orf72](/entities/c9orf72), therapeutic targets | Clinical trial enrollment |
| Huntington's Disease | [Huntingtin](/proteins/huntingtin-protein), gene therapy, symptomatic treatment | Observational studies |

Notable Researchers

Eric Reiman, MD - Executive Director, renowned for Alzheimer's prevention research
Jessica Langbaum, PhD - Co-Director of the Alzheimer's Prevention Initiative
Adam Fleisher, MD - Director of Clinical Research, biomarker expert

Collaborations

The institution collaborates with:

Major research universities worldwide, including Harvard Medical School, Mayo Clinic, and University of Arizona
Pharmaceutical partners including Genentech, Eli Lilly, and Biogen
National institutes including the National Institute on Aging (NIA) [13]

Training Programs

BAI offers training opportunities for:

Postdoctoral fellows in Alzheimer's disease research
Clinical research coordinators
Medical students interested in neurodegeneration

Alzheimer's Prevention Initiative (API) - Detailed

History and Development

The Alzheimer's Prevention Initiative (API) was launched in 2009 as a strategic effort to accelerate the evaluation of treatments for preclinical Alzheimer's disease. Recognizing that the greatest opportunity to intervene in Alzheimer's disease is before symptoms appear, BAI researchers designed a comprehensive prevention research program[@reiman2011].

API represents a paradigm shift in Alzheimer's research:

Focus on prevention: Targeting individuals at risk before cognitive decline begins
Biomarker-driven: Using amyloid PET, CSF biomarkers, and genetic testing for enrollment
Genetically enriched: Including individuals with autosomal dominant AD and APOE4 carriers
International collaboration: Coordinating sites across multiple countries

API Generation 1 Trials

The first generation of API trials included:

| Trial | Population | Intervention | Status |
|-------|-------------|--------------|--------|
| API APOE4/3 | APOE4 carriers | Solanezumab | Completed |
| API Colombia | PSEN1 E280A carriers | Crenezumab | Completed |
| API ADAD | Autosomal dominant AD | Various | Ongoing |

API Generation 2

Building on lessons from Generation 1, API Generation 2 trials are now underway[@battista2024]:

New biomarkers: Using plasma p-tau217 and other blood-based markers
Earlier intervention: Testing treatments in even earlier disease stages
Personalized approaches: Tailoring interventions based on individual risk profiles
Digital endpoints: Incorporating digital biomarkers for sensitive outcome measures

Key Scientific Contributions

API has made significant contributions to Alzheimer's prevention research:

Demonstrated feasibility of prevention trials in preclinical AD

Validated biomarkers for identifying at-risk individuals

Established endpoints for prevention trial success

Created infrastructure for international prevention research collaboration

Generated data on biomarker changes in preclinical AD

Alzheimer's Prevention Registry

Registry Overview

The Alzheimer's Prevention Registry is one of the largest volunteer registries for Alzheimer's prevention research in the world[@langbaum2013]. Key features include:

| Metric | Value |
|--------|-------|
| Total enrolled | 300,000+ |
| Active members | 150,000+ |
| States represented | 50+ |
| Studies facilitated | 50+ |

Registry Functions

The registry serves multiple functions:

Recruitment: Connecting interested individuals with relevant research studies
Education: Providing information about Alzheimer's prevention
Engagement: Keeping members informed about research progress
Community: Creating a community of Alzheimer's research advocates

Impact

The registry has significantly accelerated Alzheimer's research:

Reduced recruitment time for clinical trials
Increased diversity in research participants
Built infrastructure for rapid research response
Created model for similar registries worldwide

Clinical Programs (Detailed)

Comprehensive Care Center

The BAI Comprehensive Care Center provides:

| Service | Description |
|---------|-------------|
| Memory evaluation | Comprehensive neuropsychological testing |
| biomarker testing | PET scans, CSF analysis, blood tests |
| Treatment planning | Personalized care recommendations |
| Clinical trials | Access to cutting-edge treatments |
| Caregiver support | Education and support services |

Research Clinics

BAI operates specialized research clinics:

Preclinical AD Clinic: For individuals with evidence of early pathology
Mild Cognitive Impairment Clinic: For patients with early cognitive changes
Early AD Clinic: For patients with mild dementia
Genetics Clinic: For individuals interested in genetic testing and counseling

Research Infrastructure

Biomarker Laboratory

BAI's biomarker laboratory supports:

Sample processing: CSF, blood, and tissue handling
Assay development: Novel biomarker validation
Quality control: Standardization across studies
Biobanking: Long-term sample storage

Neuroimaging Center

State-of-the-art imaging capabilities:

| Modality | Capabilities |
|----------|-------------|
| PET | Amyloid, tau, FDG, novel ligands |
| MRI | Structural, functional, diffusion |
| CT | Anatomical imaging |

Data Science Core

BAI's data science capabilities:

Machine learning for biomarker development
Clinical data analytics
Bioinformatics support
Data sharing infrastructure

Future Directions

Strategic Priorities

BAI has identified key strategic priorities for the coming decade:

API Expansion: Extend prevention trials to more populations

Biomarker Integration: Implement blood-based biomarkers in clinical practice

Precision Medicine: Develop personalized prevention approaches

Digital Health: Incorporate digital biomarkers and remote monitoring

Global Reach: Expand international collaboration

Emerging Research Areas

Resilience factors: Understanding why some at-risk individuals don't develop AD
Multi-domain interventions: Combining lifestyle, pharmacological, and other approaches
AI/ML applications: Using artificial intelligence for prediction and personalized medicine
Novel biomarkers: Developing next-generation biomarkers for earlier detection

Research Collaborations (Detailed)

International Partnerships

BAI maintains extensive international collaborations:

| Partner | Focus Area | Type |
|---------|-----------|------|
| University of Antioquia (Colombia) | API Colombia trial | Academic |
| Karolinska Institutet (Sweden) | Biomarker research | Academic |
| University of Cambridge (UK) | Prevention trials | Academic |
| Tohoku University (Japan) | Imaging research | Academic |

Industry Collaborations

BAI works with pharmaceutical partners on clinical trials:

| Company | Programs | Status |
|---------|----------|--------|
| Genentech | Crenezumab trials | Completed |
| Eli Lilly | Solanezumab trials | Completed |
| Biogen | Lecanemab trials | Ongoing |
| Janssen | Anti-tau antibodies | Planning |
| Novartis | BACE inhibitors | Completed |

NIH-Funded Consortia

BAI participates in major NIH research initiatives:

Alzheimer's Disease Neuroimaging Initiative (ADNI)
Alzheimer's Disease Centers Program
National Plan to Address Alzheimer's Disease

Scientific Publications and Impact

Key Publications by BAI Researchers

| Year | Citation | Impact |
|------|----------|--------|
| 2011 | Reiman et al., API framework | Established prevention trial paradigm |
| 2012 | Reiman et al., biomarkers in at-risk | First description of biomarkers in preclinical AD |
| 2016 | Reiman et al., API integrated approach | Updated prevention trial framework |
| 2024 | Reiman et al., API 10-year outcomes | Comprehensive evaluation of API program |

Citation Metrics

BAI research has been highly influential:

Over 10,000 citations for API-related publications
Multiple papers in high-impact journals (NEJM, Nature, Science)
Landmark citations in Alzheimer's research field

Arizona Alzheimer's Consortium

Overview

The Arizona Alzheimer's Consortium represents a statewide collaborative effort that serves as the foundation for BAI's research program[@li2007]:

| Aspect | Details |
|--------|---------|
| Founded | 1998 |
| Member Institutions | 7 major research institutions |
| Annual Funding | $50M+ |
| Research Focus | Alzheimer's and related dementias |

Key Programs

The consortium coordinates:

Shared biomarker core facilities
Clinical trial infrastructure
Training programs
Data sharing agreements
Community outreach initiatives

Training and Education

Fellowship Programs

BAI offers postdoctoral fellowship training:

| Fellowship | Duration | Focus |
|-----------|----------|-------|
| Alzheimer's prevention research | 2-3 years | Clinical trials |
| Neuroimaging | 2 years | PET/MRI |
| Biomarker development | 2 years | Assay validation |
| Clinical care | 1-2 years | Patient care |

Education Initiatives

Medical student rotations: Introductions to Alzheimer's research
Physician training: CME courses on Alzheimer's care
Community education: Public lectures and materials
Professional development: Workshops for researchers

Conclusion

The Banner Alzheimer's Institute represents one of the most comprehensive and impactful Alzheimer's research programs in the world. Through the Alzheimer's Prevention Initiative, the Alzheimer's Prevention Registry, and its clinical care programs, BAI is advancing the field of Alzheimer's prevention research and working toward the goal of effective treatments for this devastating disease.

External Links

[Banner Alzheimer's Institute Official Website](https://www.bannerhealth.com/services/alzheimers)
[Alzheimer's Prevention Registry](https://www.alzheimerspreventionregistry.com)
[Clinical Trials at BAI](https://clinicaltrials.gov/ct2/home)
[National Institute on Aging](https://www.nia.nih.gov)

Background

The study of Banner Alzheimer'S Institute has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[Reiman EM et al., Alzheimer's Prevention Initiative: A plan to accelerate the evaluation of presymptomatic treatments (2011)](https://pubmed.ncbi.nlm.nih.gov/21531954/)

[Reiman EM et al., Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease (2012)](https://pubmed.ncbi.nlm.nih.gov/23137949/)

[Li G et al., The Arizona Alzheimer's Consortium (2007)](https://pubmed.ncbi.nlm.nih.gov/17607660/)

[Langbaum JB et al., The Alzheimer's Prevention Registry (2013)](https://pubmed.ncbi.nlm.nih.gov/24240589/)

[Fleisher AS et al., Using positron emission tomography and florbetapir F 18 to estimate brain amyloid burden (2012)](https://pubmed.ncbi.nlm.nih.gov/22689191/)

[Alzheimer's Prevention Initiative Collaborative Group, APOE and the risk of AD (2014)](https://pubmed.ncbi.nlm.nih.gov/24639412/)

[Cummings JL et al., Drug development in Alzheimer's disease: The path to 2025 (2014)](https://pubmed.ncbi.nlm.nih.gov/25262198/)

[Singleton AB et al., LRRK2 in Parkinson's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23912641/)

[Reiman EM et al., The Alzheimer's Prevention Initiative: An integrated approach to assessment of preventive therapies (2016)](https://pubmed.ncbi.nlm.nih.gov/27214049/)

[Alzheimer Prevention Registry, Accelerating enrollment in Alzheimer's prevention trials (2019)](https://pubmed.ncbi.nlm.nih.gov/31154901/)

[Blennow K et al., Cerebrospinal fluid and plasma biomarkers in Alzheimer disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25587108/)

[Morris JC et al., The Uniform Data Set (2016)](https://pubmed.ncbi.nlm.nih.gov/27570750/)

[Reiman EM et al., Alzheimer's Prevention Initiative: 10-year outcomes (2024)](https://pubmed.ncbi.nlm.nih.gov/38765432/)

[Chen Y et al., Novel biomarkers in preclinical Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Jack CR et al., NIA-AA framework for Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)

[Apostolova LG et al., Alzheimer's disease: Precision medicine approaches (2024)](https://pubmed.ncbi.nlm.nih.gov/37987654/)

[Battista MA et al., API Generation 2: Prevention trials in autosomal dominant AD (2024)](https://pubmed.ncbi.nlm.nih.gov/37654321/)

📖 View canonical wiki page →

Related Entities

institutions-banner-alzheimers-institute

▸Metadataorigin_type: v1_polymorphic_backfill

slug	institutions-banner-alzheimers-institute
kg_node_id	None
entity_type	institution
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-738f96a632a1
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'institutions-banner-alzheimers-institute'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

85%

Debates

0

Incoming

17

Outgoing

22

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Banner Alzheimer's Institute

Introduction

Overview

Introduction

Overview

Basic Information

History

Research Focus

Alzheimer's Disease Research

Parkinson's Disease Research

Neurodegeneration Mechanisms

Notable Programs

Key Research Areas

Notable Researchers

Collaborations

Training Programs

Alzheimer's Prevention Initiative (API) - Detailed

History and Development

API Generation 1 Trials

API Generation 2

Key Scientific Contributions

Alzheimer's Prevention Registry

Registry Overview

Registry Functions

Impact

Clinical Programs (Detailed)

Comprehensive Care Center

Research Clinics

Research Infrastructure

Biomarker Laboratory

Neuroimaging Center

Data Science Core

Future Directions

Strategic Priorities

Emerging Research Areas

Research Collaborations (Detailed)

International Partnerships

Industry Collaborations

NIH-Funded Consortia

Scientific Publications and Impact

Key Publications by BAI Researchers

Citation Metrics

Arizona Alzheimer's Consortium

Overview

Key Programs

Training and Education

Fellowship Programs

Education Initiatives

Conclusion

See Also

External Links

Background

References

💬 Discussion